Skip to main content

#PreventiveNeurology: is life a sexually transmitted neurodegenerative disease?

Age is a disease vs. Ageing as a natural biological process: have your say #PreventiveNeurology #HealthyAgeing

I have always cracked the joke 'that life is a sexually transmitted neurodegenerative disease with a 100% mortality'. This usually gets a mutated laugh until people start pondering the implications of the joke and realise that I am being serious.




Evolution never designed, and selected, the human brain and nervous system to function much past 35 years of age. It is only relatively recently that life expectancy has increased with the requirement of our brains to function into old age. It is clear that when we measure cognitive function, and brain volume, it is all downhill from about 35 years of age. Those of us who are older than 35 notice the subtle cognitive impairments that increase with age and the gradual malfunction of our nervous systems. When last have you tried tight-rope walking? Your failing balance system is simply a reflection of the global rot that is also shredding your cognition. Fortunately we have enough reserve to adapt and cope with slow decline in our mental faculties. However, if we live long enough we are all likely to become demented. Dementia in this setting is simply the reduction of cognition to a point when you can't manage socially and need help. To prevent the inevitable consequence of ageing is there anything we can do to optimise our brain health so our 'brains outlive' our bodies. 

How to optimise brain health so that we die of a systemic disease with our cognition relatively intact is the aim of our #PreventiveNeurology campaign. Maybe we should call it #HealthyAgeing? We have hypothesised, based on scientific principles, that there is a lot we can do to improve brain health. However, some of the interventions may require the administration of medications. For this to happen and be adopted by society we need to make ageing a disease. By defining ageing as a disease it changes everything. Firstly, it creates the incentives for the pharmaceutical industry to invest in the necessary R&D to get drugs to market. If ageing is a disease healthcare systems will pay for interventions. The corollary is that if ageing is not defined as a disease any interventions, to delay or modify ageing, will be limited to lifestyle interventions. By defining ageing as a disease it will allow us to develop tools for population screening to identify people who are either healthy or in the presymptomatic phase of known neurodegenerative disease. This will then allow us to test preventive strategies to delay the onset of symptomatic disease. 


This is why we want to shift the 'defining of ageing as a disease' debate centre stage! Please have your say. 

Comments

  1. Interesting take on things. I am prepared to have a disease called life if it leads to an improvement in my quality of life. I am interested to know what are your drug targets.

    ReplyDelete
    Replies
    1. Re: 'Drug targets'. At moment is based on reducing your cardiovascular risk, therefore antihypertensives, statins and aspirin. This is not rocket science.

      Delete

Post a Comment

Popular posts from this blog

#BrainHealth: another reason to hate margerine

Information rarely changes health outcomes on its own, which is why we need policy #PreventiveNeurology #BrainHealth
Although we have known about the cardiovascular risks associated with the consumption of trans fatty acids (TFAs) for decades little has been done by individuals to reduce their consumption. Therefore when the state of New York put in place restrictions on their use in 11 counties between 2007 and 2011 they set-up an experiment. This experiment now reports out: the study below included 25 counties and compared cardiovascular outcomes in the TFA non-restricted populations of 14 counties with the populations in the 11 TFA restricted counties. Three or more years after restrictions were put in place the people living in the counties with TFA restrictions experienced a significant decline in combined myocardial infarction and stroke events (-6.2%) compared with the TFA non-restricted populations. 

I sincerely hope you appreciate the significance of these findings? 

Lessons lea…

#BrainHealth: you are what you eat?

If you take #BrainHealth seriously you need to focus on diet.


Do you buy into 'you are what you eat'? This ambitious systematic literature review has identified 10 foods and 7 nutrients with evidence for causal cardio-metabolic effects. Any intervention that reduces your vascular risk burden should reduce all-cause dementia and improve your Brain Health. 

The foods that were found to have protective effects: fruitsvegetablesbeans/legumesnuts/seedswhole grainsfishyogurtfibreseafood omega-3spolyunsaturated fatspotassiumThe food found to have harmful effects:  unprocessed red meatsprocessed meatssugar-sweetened beveragesglycemic load (sugar or carbohydrates)trans-fatssodium/salt. There is nothing new here and most of this should be obvious to you and is currently included in mots dietary guidelines. The elephant in the room is economics; in modern economies people eat what they can afford. Modifying the nation's diet is going to need a rethink about how we encourage a healthy die…

#PredictPD: Is this the disease modifying therapy the PD community has been waiting for?

Is exenatide the game-changer we need in Parkinson's disease? #PreventiveNeurology #PredictPD
Would you participate in a study to define your future risk of getting Parkinson's Disease (PD)? In other words would you like to know you are likely to develop PD in the future? A lot of people answer by saying it depends if you have a treatment to prevent PD. At present we don't, but the study below of a exenatide,  a glucagon-like peptide-1 (GLP-1) receptor agonist, suggests it may be neuroprotective in patients with established PD. If this study's findings are confirmed in larger phase 3 studies and leads to exenatide being licensed as a disease-modifying therapy, or DMT, for PD changes all this. This means we can take people at high-risk of developing PD and randomise them to receive either placebo or exenatide to see if it can prevent, or at least delay the onset of, PD. This study alone creates the incentive for people from the general public to participate in population…